A Chat with Bernie Iliakis of CorneaGen - Takeaways - MDSpire

A Chat with Bernie Iliakis of CorneaGen

Bernie Iliakis, president and CEO of CorneaGen, discusses the growing momentum of CTAK to treat keratoconus, how the company is meeting the growing demand for DMEK and DSAEK tissue processing, and more.

  • November 1, 2025

  • 4 min

Share

  • 1

    CorneaGen launched Corneal Tissue Addition for Keratoplasty (CTAK) in June 2024, improving sight for keratoconus patients.

  • 2

    CTAK utilizes custom, gamma-irradiated, non-immunogenic corneal tissue inlays tailored to individual patient needs.

  • 3

    CorneaGen has performed over 1,000 CTAK procedures in the U.S. and expanded its reach internationally by September 2025.

  • 4

    The organization pioneered innovations in corneal transplantation, including the use of amphotericin B in storage media.

  • 5

    Bernie Iliakis, CorneaGen's CEO, emphasizes the importance of personal connections in corneal donation and transplantation.

Original Source(s)

A Chat with Bernie Iliakis of CorneaGen

  • November 1, 2025

Related Content

Texas First for Epioxa Therapy

The first US rollout of FDA-approved epi-on cross-linking aims to improve comfort and recovery for keratoconus patients

  • May 6, 2026

  • 2 min
Determinants of Astigmatism in Grafts Following Corneal Transplantation for Keratoconus

Keratoconus Care Continues to Evolve

Susan Gromacki, OD, MS, FAAO, FSLS, Dipl AAO, and Clark Chang, OD, FAAO, FSLS, reviewed the latest developments in diagnosis, imaging, contact lenses, corneal cross-linking (CXL), and surgical management for KC.